Evofem Biosciences Reports First Quarter 2020 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Evofem Biosciences (EVFM) Misses Q1 EPS by 8c
May 6, 2020 8:05 AM EDTEvofem Biosciences (NASDAQ: EVFM) reported Q1 EPS of ($0.40), $0.08 worse than the analyst estimate of ($0.32).
"We are now less than three weeks away from the PDUFA date for Phexxi and the potential to deliver the first non-hormonal contraceptive innovation in decades. We are... More
